B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

The Waltham biotech signs more pharma deals than the average company, and already lists Vertex, Takeda and Biogen as its ...

Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts ...

Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

And one of the best ways to cash in on that is to invest in stocks that can exceed the market's performance. Two that look ...

In Phase III studies, Tonmya showed significantly superior analgesic effects in patients with fibromyalgia versus placebo.

Vertex Pharmaceuticals is catching the eyes of bullish analysts, predicting a robust uptrend. Revenue trends and technical ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Vertex Pharmaceuticals' Seaport headquarters buildings have been refinanced for $1 billion, putting a ten-figure value on an ...

Martin Mwita returned home to Bellevue this spring after becoming among the first in the country to receive one of two new gene therapies for sickle cell disease in St.